CANY
AUTL

Caxton Associates (New York)’s Autolus Therapeutics AUTL Stock Holding History

Caxton Associates (New York)’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-84,156
Closed -$180K – 452
2022
Q3 		$180K Sell
84,156
-5,200
-6% -$15.4K 0.02% 411
2022
Q2 		$253K Hold
89,356
– – 0.02% 420
2022
Q1 		$373K Buy
89,356
+28,714
+47% +$121K 0.03% 320
2021
Q4 		$315K Buy
+60,642
New +$364K 0.03% 401

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Caxton Associates (New York)'s AUTL Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Autolus Therapeutics (AUTL) in Q4 2022, closing a stake of 84,156 shares — an estimated $180K sold.

Caxton Associates (New York) first reported a position in AUTL in Q4 2021 and held it in 4 quarters. The position peaked at $373K in Q1 2022. 71 funds tracked by Wall St. Rank hold AUTL as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Autolus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 84,156 Autolus Therapeutics shares in Q4 2022, an estimated $180K.
  • Caxton Associates (New York) first reported a position in Autolus Therapeutics in Q4 2021 and held it in 4 quarters.
  • Caxton Associates (New York)'s Autolus Therapeutics position peaked at $373K in Q1 2022.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.